‘Obsessive’ Teva Aims For $800m Biosimilar Sales By 2027

Israeli Firm Plans To Double Revenues With Five Near-Term Launches

 
• By Dean Rudge
  
Teva Pharmaceuticals
• Source: Shutterstock

More from Strategy

More from Generics